A study on the effect of diabetes drugs (SGLT2 inhibitor and DPP4 inhibitor) for nonalcoholic fatty liver disease
Latest Information Update: 19 Nov 2020
At a glance
- Drugs Dapagliflozin (Primary) ; Teneligliptin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 13 Nov 2020 Status changed from active, no longer recruiting to completed.
- 15 May 2018 Status changed from not yet recruiting to active, no longer recruiting.
- 16 May 2017 New trial record